Michelle Roland, M.D., an Assistant Professor of Medicine in the UCSF Positive Health Program at San Francisco General Hospital, notes that before people with HIV began doing so much better, "it was felt that it didn't make sense to take a very scarce resource and allocate that resource to a patient population that wasn't likely to benefit from it for very long. As fewer people [in the US] die from traditionally defined opportunistic infections, they're developing the complications of hepatitis B and C, including end stage organ failure. There's an increasing need to consider the safety and efficacy of organ transplants."
Also, according to Dr. Roland, since HIV itself "is a disease of immunosuppression, there has been substantial concern that the post transplant immunosuppression might cause acceleration of HIV disease progression." Nevertheless, some immunologists wonder if suppressing the generalized activation of the immune system might even be beneficial to people with HIV, although no study has yet shown this.
Dr. Roland sees many patients with end stage liver disease. She says, "Transplant is not the right option for a lot of people. It's a very personal decision. They have to ask themselves, 'Do I want to step into this high-tech medical intervention with all these potential complications and have the possibility of the end of my life being in an intensive care unit?'"
At the 9th Conference on Retroviruses and Opportunistic Infections in February, Dr. Roland presented data on 41 HIV-positive transplant recipients who would have been eligible for the UCSF protocol (no history of opportunistic infections and fully suppressed or suppressible virus). Half of them had received livers and the other half kidneys. Half of these patients had a follow up of at least 279 days and were compared with one-year survival data collected by the organization that monitors transplants. The HIV-positive recipients fared almost as well as people who were HIV-negative. HIV viral load remained relatively controlled and there were only two opportunistic infections. A 15-year-old boy had CMV esophagitis and hepatitis C recurrence with a relatively high T-cell count and died. Another recipient had Candida esophagitis that responded very quickly to treatment.
However, eight patients who did not meet the eligibility criteria for the protocol didn't fare so well. There were two cases of PML and one case of MAC. This is the justification for the rather strict entry requirements for the study. Dr. Roland will give an update on how people are doing at the International AIDS Conference in Barcelona in July.
There are plans to open up the protocol gradually to people with a history of opportunistic infections and, possibly, detectable viral load, once safety and efficacy have been demonstrated in the more conservatively chosen patients.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|Separate and Unequal Access Frames Discussion at CROI Panel on U.S. HIV Care Cascade|
|CROI 2018: Highlights and What's Next for Advocates|
|Reported PrEP 'Failure' Most Likely a Lack of Proper Testing and Adherence|
|Injection Drug Use Among People Living With HIV: A Missed Opportunity to Save Lives|
|Statin Use Might Reduce Risk of Cancer in HIV-Positive People|
|Insurers and Pharmas Must Help Fix HIV Drug Pricing System, Advocates Say|